Innate Pharma S.A. (IPHA) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nkarta (NKTX) has outperformed Innate Pharma S.A. (IPHA) over the past year, gaining 10.2% versus a loss of 22.1%. Over five years, IPHA leads with a -74.1% price change compared with -87.6% for NKTX. Innate Pharma S.A. is the larger company by market cap ($169.8 million vs $162.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPHA | NKTX |
|---|---|---|
| Share price | $1.52 | $2.27 |
| Market cap | $169.78M | $162.59M |
| 1-day change | -4.40% | -1.73% |
| YTD return | -13.14% | +22.70% |
| 1-year return | -22.05% | +10.19% |
| 5-year return | -74.11% | -87.62% |
| EPS (TTM) | $-0.59 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.71 | $3.72 |
| 52-week low | $1.17 | $1.70 |
| Distance from 52-week high | -43.91% | -38.98% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +338.82% | +377.09% |
| Average volume | 158.98K | 618.67K |
| Shares outstanding | 111.70M | 71.62M |
| Employees | 120 | 106 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed IPHA by 32.2 percentage points over the past year.
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Healthcare · Biotechnology · 120 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Healthcare · Biotechnology · 106 employees
IPHA vs NKTX FAQ
Which is bigger, Innate Pharma S.A. or Nkarta?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $169.78M compared with $162.59M for Nkarta (NKTX).
Which stock has performed better over the past year, IPHA or NKTX?
NKTX returned +10.19% over the past 12 months, compared with -22.05% for IPHA (price return, excluding dividends). Past performance does not predict future results.
Are Innate Pharma S.A. and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.